Full Press Release Details
ADC Therapeutics Announces Online Publication
of Camidanlumab Tesirine
Phase 1 Results in The Lancet Haematology
Camidanlumab tesirine (Cami) demonstrated anti-tumoral
activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivotal Phase 2 trial
LAUSANNE, Switzerland, May 26, 2021 -
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs)
to treat hematological malignancies and solid tumors, today announced that results of the Phase 1 clinical trial of camidanlumab tesirine
(Cami), an anti-CD25 ADC, in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas have been published online in The
"There is a significant unmet medical need
for novel therapies that improve outcomes in patients with relapsed or refractory Hodgkin lymphoma," said Mehdi Hamadani, MD, Professor
of Internal Medicine at the Medical College of Wisconsin, Division of Hematology & Oncology and lead author of The Lancet
Haematology paper. "This patient population is often heavily pretreated, as was the case in this published study in which
patients experienced a median of five previous systemic therapies. The Phase 1 study demonstrates encouraging potential for Cami to provide
a new treatment option for patients with relapsed or refractory Hodgkin lymphoma."
The multicenter, open-label, single-arm, dose
escalation and dose expansion Phase 1 clinical trial enrolled 133 adult patients, 77 (58%) with classical Hodgkin lymphoma and 56 (42%)
with non-Hodgkin lymphoma. Enrolled patients were required to have pathologically confirmed relapsed or refractory Hodgkin lymphoma or
non-Hodgkin lymphoma and no therapies with established clinical benefit for their disease stage available to them.
"We're pleased the results of our
Phase 1 trial of Cami in patients with relapsed or refractory lymphoma have been published in The Lancet Haematology," said
Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer at ADC Therapeutics. "The positive results in patients with
Hodgkin lymphoma guided the design of our pivotal Phase 2 trial, which has completed enrollment. We're continuing to follow patients
and look forward to presenting data from the Phase 2 Cami trial at an upcoming congress."
Key results include:
the data from this Phase 1 clinical trial, a Phase 2 trial to further evaluate the safety and efficacy of Cami in patients with relapsed
or refractory Hodgkin lymphoma is ongoing. Interim data from the pivotal Phase 2 trial presented at the 2020 American Society of Hematology
meeting demonstrated encouraging antitumor activity as a single agent with an ORR of 83%, a complete response rate of 38% and no new safety
signals. These data highlight the potential for Cami to address an unmet need in heavily pretreated patients (median of seven prior lines
of systemic therapy).
For information about the ongoing pivotal Phase
2 clinical trial of Cami in patients with relapsed or refractory Hodgkin lymphoma, please visit https://clinicaltrials.gov/ (identifier
About Camidanlumab Tesirine (Cami)
Camidanlumab tesirine (Cami, formerly ADCT-301)
is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax -TAC, licensed from Genmab A/S),
conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized into
the cell where enzymes release the PBD-based payload, killing the cell. This applies to CD25-expressing tumor cells and also to CD25-expressing
Tregs. The intra-tumoral release of its PBD payload may also cause bystander killing of neighboring tumor cells, and PBDs have also been
shown to induce immunogenic cell death. All of these properties of Cami may enhance immune-mediated anti-tumor activity.
Cami is being evaluated in a pivotal Phase 2 clinical
trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The Company
is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and
ADC Therapeutics' CD19-directed ADC ZYNLONTA
(loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents. Cami (camidanlumab
tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial
for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based ADCs in ongoing clinical and preclinical
ADC Therapeutics is based in Lausanne (Biop le),
Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/
and follow the Company on Twitter and LinkedIn.